Atrial Fibrillation
Conditions
Keywords
atrial fibrillation, progression, left atrial function
Brief summary
The purpose of this study is to investigate the presence and magnitude of structural changes of the heart and their long-term development in young patients with atrial Fibrillation (AF), studied by echocardiographic measurements and plasma biomarkers and their association to AF burden, studied using long-term ECG
Detailed description
100 patients with symptomatic Atrial Fibrillation diagnosis are included. Diagnosis is set either at the index visit or within 12 months before inclusion. . The follow up period is 5 years. Patients presenting with AF in connection with acute infection, acute cardiac ischemia, surgery or thyroid disease are excluded. Further, AF patients with cardiomyopathies, known genetic diseases and congenital cardiac abnormalities are also excluded. At inclusion patients undergo an in-depth interview regarding comorbidities, medication, previous treatments related to the AF diagnosis. In addition, baseline data for weight and height are collected. In connection to inclusion the patients are asked leave venous bloodwork (Na, K, Creatinine, plasma Glucose and NTproB-Type Natriuretic Peptide). An echocardiographic exam is performed according to a prespecified protocol with special emphasis on the left atrial function and anatomy. This is followed by a continuous ECG recording for 14 days using BioTel ePatch. The ECG patch is later returned to a core facility by mail. The patients´ are followed for five years and are asked to leave bloodwork and perform a 14-day ECG recording yearly. After these exams, a follow up phone call is placed to the patient aimed at documenting clinical progress related to symptoms, treatment and interventions. After 5 years follow up patients undergo a follow up echocardiographic exam in addition to yearly bloodwork and ECG recording. The patients´ clinical symptoms are treated at the clinician´s discretion according to current guidelines.
Interventions
None listed
Sponsors
Boehringer Ingelheim
Karolinska Institutet
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
* Atrial fibrillation * Diagnosis of atrial fibrillation within one year of inclusion
Exclusion criteria
* Duration of atrial fibrillation over one year. * Acute stressor for atrial fibrillation such as: acute ischemic heart disease or infection
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Development of atrial fibrillation burden | change from baseline at 5 years | Change in burden of atrial fibrillation expressed as proportion of arrhythmia present on long-term ECG yearly |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Development of atrial electrocardiographic status | Change from baseline at 5 years | Change in number of supraventricular ectopic beats per 24 h on long-term ECG Yearly |
| Development of supraventricular ectopies | Change from baseline at 5 years | Change in numbers of supraventricular tachycardia runs of at least 20 beats per 24 h on long-term ECG yearly |
| Development of atrial fibrillation incident | Change from baseline at 5 years | Change in numbers of atrial fibrillation episodes per 24 h on long-term ECG yearly |
| Development of humoral measures of hemodynamic status | Change from baseline at 5 years | Change in levels of plasma-N-terminal pro brain natriuretic peptide yearly (ng) |
| Development of left atrial systolic function by echocardiography | Change from baseline at 5 years | Change in left atrial strain (%) |
| Development of left atrial volume by echocardiography | Change from baseline at 5 years | Change in left ventricular volume indexed (ml/m2) |
| Development of left ventricular systolic function by echocardiographic | Change from baseline at 5 years | Change in left ventricular ejection fraction (%) |
| Development of echocardiographic status | Change from baseline at 5 years | Change in the left atrial volume indexed (ml/m2) |
Countries
Sweden
Contacts
Primary ContactPiotr Sobocinski Doliwa, M.D. Ph.D.
Backup ContactJohan Engdahl, MD PhD
Outcome results
None listed